Eurand Initiates Rolling NDA For Zentase To Treat Pancreatic Insufficiency
This article was originally published in The Pink Sheet Daily
Executive Summary
Fewer competitors expected as FDA’s 2008 PEP guidance deadline looms; market worth $300 million to $700 million, firm tells “The Pink Sheet” DAILY.